Incidental Resolution of a Radiation-Induced Cavernous Hemangioma of the Brain following the Use of Bevacizumab in a Child with Recurrent Medulloblastoma
被引:14
作者:
Aguilera, Dolly
论文数: 0引用数: 0
h-index: 0
机构:
Emory Univ, Dept Hematol Oncol, Atlanta, GA 30322 USANorthwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Dept Hematol Oncol, Chicago, IL 60614 USA
Aguilera, Dolly
[3
]
Tomita, Tadanori
论文数: 0引用数: 0
h-index: 0
机构:
Childrens Mem Hosp, Dept Neurosurg, Chicago, IL 60614 USANorthwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Dept Hematol Oncol, Chicago, IL 60614 USA
Tomita, Tadanori
[2
]
Goldman, Stewart
论文数: 0引用数: 0
h-index: 0
机构:Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Dept Hematol Oncol, Chicago, IL 60614 USA
Goldman, Stewart
Fangusaro, Jason
论文数: 0引用数: 0
h-index: 0
机构:
Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Dept Hematol Oncol, Chicago, IL 60614 USANorthwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Dept Hematol Oncol, Chicago, IL 60614 USA
Fangusaro, Jason
[1
]
机构:
[1] Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Dept Hematol Oncol, Chicago, IL 60614 USA
[2] Childrens Mem Hosp, Dept Neurosurg, Chicago, IL 60614 USA
[3] Emory Univ, Dept Hematol Oncol, Atlanta, GA 30322 USA
Radiation-induced cavernous hemangiomas (RICH) are a known complication of radiation exposure, especially in young children. The current treatment approaches to these lesions include observation and surgical resection. We report the case of a 4-year-old male with recurrent medulloblastoma who had resolution of an incidental RICH lesion while being treated with bevacizumab for his recurrent brain tumor. There was no evidence of worsening hemorrhage with this therapy and the RICH did not recur upon discontinuation of the chemotherapy regimen. This is the first documented case of a RICH lesion responding to antiangiogenic therapy, suggesting the possible use of this class of agents in the treatment of symptomatic patients who are not considered appropriate candidates for surgical resection. Although the risk of bleeding must be taken into consideration, antiangiogenic therapies have the potential to be a novel treatment modality for symptomatic RICH lesions. Copyright (C) 2010 S. Karger AG, Basel
机构:
US FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USAUS FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Cohen, Martin H.
;
Shen, Yuan Li
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USAUS FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Shen, Yuan Li
;
Keegan, Patricia
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USAUS FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Keegan, Patricia
;
Pazdur, Richard
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USAUS FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
机构:
US FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USAUS FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Cohen, Martin H.
;
Shen, Yuan Li
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USAUS FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Shen, Yuan Li
;
Keegan, Patricia
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USAUS FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
Keegan, Patricia
;
Pazdur, Richard
论文数: 0引用数: 0
h-index: 0
机构:
US FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USAUS FDA, Div Biol Oncol Prod, Off Oncol Drug Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA